Research Article
Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy
Table 3
Univariate and multivariate analyses of association between clinical parameters and time to progressive disease.
| | Clinical features | Patient numbers | Univariate | Multivariate | HR†
(95% CI‡) | P-value | HR†
(95% CI‡) | P-value |
| | Stage (I vs II vs III) | 13 : 27 : 65 | - | 0.008∗ | 1.668
(1.040-2.676) | 0.035∗ |
| | Tumor site (Upper vs Middle vs Lower) | 28 : 48 : 29 | - | 0.514 | - | - |
| | Gender (Male vs Female) | 98 : 7 | 0.388
(0.069-0.736) | 0.014∗ | 2.184
(0.947-5.040) | 0.068 |
| | Age (≥ vs <60 years old) | 40 : 65 | 0.766
(0.434-1.303) | 0.309 | - | - |
| | Surgery (Yes vs No) | 38 : 67 | 1.850
(1.090-2.996) | 0.022∗ | 0.413
(0.225-0.760) | 0.005∗ |
| | Radiotherapy (4000~5000cGy vs >5000cGy) | 40 : 65 | 0.779
(0.469-1.301) | 0.348 | - | - |
| | Days from diagnosis to initial treatment (< v.s ≥29) | 57 : 48 | 1.251
(0.758-2.062) | 0.382 | - | - |
| | Days from diagnosis to complete treatment (< v.s ≥69) | 54 : 51 | 0.821
(0.493-1.354) | 0.433 | - | - |
| | Hematologic Markers |
| | Platelet count of pre-treatment (≥ vs <300,000/μL) | 34 : 71 | 0.580
(0.303-0.956) | 0.035∗ | 1.326
(0.681-2.582) | 0.409 |
| | Platelet count of post-treatment (≥ vs <300,000/μL) | 9 : 96 | 0.456
(0.105-0.960) | 0.042∗ | 2.538
(1.024-6.291) | 0.045∗ |
| | MPV§ (≥ vs <9.8fl) | 51 : 50& | 0.849 (0.508-1.411) | 0.522 | - | - |
| | Hemoglobin (≥ vs <14g/dL) | 17 : 88 | 1.402
(0.754-2.477) | 0.303 | - | - |
| | White blood count (≥ vs <10,000/μL) | 12 : 93 | 0.648
(0.230-1.516) | 0.274 | - | - |
| | Absolute Neutrophil count (≥ vs <4483/μL) | 53 : 52 | 0.740
(0.444-1.218) | 0.232 | - | - |
| | Neutrophil percentage (≥ vs <73.4%) | 53 : 52 | 0.809
(0.490-1.332) | 0.403 | - | - |
| | Absolute Monocyte count (≥ vs <449/μL) | 53 : 52 | 0.961
(0.583-1.583) | 0.874 | - | - |
| | Monocyte percentage (≥ vs <7%) | 53 : 52 | 0.803
(0.486-1.321) | 0.385 | - | - |
| | Absolute lymphocyte counts (≥ vs <1042/μL) | 53 : 52 | 1.615
(0.987-2.725) | 0.056 | - | - |
| | Lymphocyte percentage (≥ vs <16%) | 53 : 52 | 1.838
(1.134-3.160) | 0.015∗ | 0.336
(0.053-2.131) | 0.250 |
| | Biomarker of Inflammation |
| | Platelet to- ratio (≥ vs <236) | 53 : 52 | 0.535 (0.309-0.865) | 0.012∗ | 0.854
(0.399-1.826) | 0.685 |
| | Platelet-to-Lymphocyte(%) ratio (≥ vs <14605) | 53 : 52 | 0.511
(0.296-0.826) | 0.007∗ | 0.971
(0.412-2.291) | 0.947 |
| | Neutrophil-to-Lymphocyte ratio (≥ vs <4.35) | 53 : 52 | 0.571
(0.339-0.933) | 0.026∗ | 0.453
(0.077-2.678) | 0.385 |
|
|
, hazard ratio; ‡CI, confidence interval; §MPV, mean platelet volume; , absolute lymphocyte count; &no data of 4 patients. |
